These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 8178349)

  • 1. BCG immunotherapy prevents recurrence of diabetes in islet grafts transplanted into spontaneously diabetic NOD mice.
    Lakey JR; Singh B; Warnock GL; Rajotte RV
    Transplantation; 1994 Apr; 57(8):1213-7. PubMed ID: 8178349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of recurrence of IDDM in islet-transplanted diabetic NOD mice by adjuvant immunotherapy.
    Wang T; Singh B; Warnock GL; Rajotte RV
    Diabetes; 1992 Jan; 41(1):114-7. PubMed ID: 1727730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nondepleting anti-CD4 and soluble interleukin-1 receptor prevent autoimmune destruction of syngeneic islet grafts in diabetic NOD mice.
    Drage M; Zaccone P; Phillips JM; Nicoletti F; Dawson J; Andrew Bradley J; Cooke A
    Transplantation; 2002 Sep; 74(5):611-9. PubMed ID: 12352875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indefinite islet protection from autoimmune destruction in nonobese diabetic mice by agarose microencapsulation without immunosuppression.
    Kobayashi T; Aomatsu Y; Iwata H; Kin T; Kanehiro H; Hisanaga M; Ko S; Nagao M; Nakajima Y
    Transplantation; 2003 Mar; 75(5):619-25. PubMed ID: 12640299
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-4 or interleukin-10 expressed from adenovirus-transduced syngeneic islet grafts fails to prevent beta cell destruction in diabetic NOD mice.
    Smith DK; Korbutt GS; Suarez-Pinzon WL; Kao D; Rajotte RV; Elliott JF
    Transplantation; 1997 Oct; 64(7):1040-9. PubMed ID: 9381527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720.
    Fu F; Hu S; Deleo J; Li S; Hopf C; Hoover J; Wang S; Brinkmann V; Lake P; Shi VC
    Transplantation; 2002 May; 73(9):1425-30. PubMed ID: 12023620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCL22 Prevents Rejection of Mouse Islet Allografts and Induces Donor-Specific Tolerance.
    Montane J; Obach M; Alvarez S; Bischoff L; Dai DL; Soukhatcheva G; Priatel JJ; Hardenberg G; Levings MK; Tan R; Orban PC; Verchere CB
    Cell Transplant; 2015; 24(10):2143-54. PubMed ID: 26423995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in suppressor of cytokine signaling-1 (SOCS-1) expressing islet allograft destruction in normal BALB/c and spontaneously-diabetic NOD recipient mice.
    Solomon M; Flodström-Tullberg M; Sarvetnick N
    Transplantation; 2005 May; 79(9):1104-9. PubMed ID: 15880051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent autoimmunity accelerates destruction of minor and major histoincompatible islet grafts in nonobese diabetic (NOD) mice.
    Okitsu T; Bartlett ST; Hadley GA; Drachenberg CB; Farney AC
    Am J Transplant; 2001 Jul; 1(2):138-45. PubMed ID: 12099361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endogenous immune response to glutamic acid decarboxylase (GAD67) in NOD mice is modulated by adjuvant immunotherapy.
    Qin HY; Elliott JF; Lakey JR; Rajotte RV; Singh B
    J Autoimmun; 1998 Dec; 11(6):591-601. PubMed ID: 9878081
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrathymic islet cell transplantation reduces beta-cell autoimmunity and prevents diabetes in NOD/Lt mice.
    Gerling IC; Serreze DV; Christianson SW; Leiter EH
    Diabetes; 1992 Dec; 41(12):1672-6. PubMed ID: 1446808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of overt diabetes and insulitis by intrathymic injection of syngeneic islets in newborn nonobese diabetic (NOD) mice.
    Nomura Y; Stein E; Mullen Y
    Transplantation; 1993 Sep; 56(3):638-42. PubMed ID: 8212162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival of microencapsulated islets at 400 days posttransplantation in the omental pouch of NOD mice.
    Kobayashi T; Aomatsu Y; Iwata H; Kin T; Kanehiro H; Hisanga M; Ko S; Nagao M; Harb G; Nakajima Y
    Cell Transplant; 2006; 15(4):359-65. PubMed ID: 16898230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoimmune destruction of islet grafts in the NOD mouse is resistant to 15-deoxyspergualin but sensitive to anti-CD4 antibody.
    Stegall MD; Loberman Z; Ostrowska A; Coulombe M; Gill RG
    J Surg Res; 1996 Aug; 64(2):156-60. PubMed ID: 8812627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged islet graft survival in NOD mice by blockade of the CD40-CD154 pathway of T-cell costimulation.
    Molano RD; Berney T; Li H; Cattan P; Pileggi A; Vizzardelli C; Kenyon NS; Ricordi C; Burkly LC; Inverardi L
    Diabetes; 2001 Feb; 50(2):270-6. PubMed ID: 11272136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of recurrent but not spontaneous autoimmune diabetes by transplanted NOD islets adenovirally transduced with immunomodulating molecules.
    Sakata M; Yasuda H; Moriyama H; Yamada K; Kotani R; Kurohara M; Okumachi Y; Kishi M; Arai T; Hara K; Hamada H; Yokono K; Nagata M
    Diabetes Res Clin Pract; 2008 Jun; 80(3):352-9. PubMed ID: 18400329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Encapsulated piscine (tilapia) islets for diabetes therapy: studies in diabetic NOD and NOD-SCID mice.
    Safley SA; Cui H; Cauffiel SM; Xu BY; Wright JR; Weber CJ
    Xenotransplantation; 2014; 21(2):127-39. PubMed ID: 24635017
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costimulation blockade of both inducible costimulator and CD40 ligand induces dominant tolerance to islet allografts and prevents spontaneous autoimmune diabetes in the NOD mouse.
    Nanji SA; Hancock WW; Luo B; Schur CD; Pawlick RL; Zhu LF; Anderson CC; Shapiro AM
    Diabetes; 2006 Jan; 55(1):27-33. PubMed ID: 16380473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depleting anti-CD4 monoclonal antibody cures new-onset diabetes, prevents recurrent autoimmune diabetes, and delays allograft rejection in nonobese diabetic mice.
    Makhlouf L; Grey ST; Dong V; Csizmadia E; Arvelo MB; Auchincloss H; Ferran C; Sayegh MH
    Transplantation; 2004 Apr; 77(7):990-7. PubMed ID: 15087759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined therapy with interleukin-4 and interleukin-10 inhibits autoimmune diabetes recurrence in syngeneic islet-transplanted nonobese diabetic mice. Analysis of cytokine mRNA expression in the graft.
    Rabinovitch A; Suarez-Pinzon WL; Sorensen O; Bleackley RC; Power RF; Rajotte RV
    Transplantation; 1995 Aug; 60(4):368-74. PubMed ID: 7652767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.